Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes mortality compared with lactitol (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes hepatic encephalopathy compared with lactitol (very low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).
1 finding from 1 review
Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Successful disimpaction · patients aged 0 to 18 years with a diagnosis of functional constipation
Lactulose showed no clear difference in successful disimpaction compared with milk of magnesia (MOM) (low certainty).
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether lactulose changes need for additional therapies compared with milk of magnesia (MOM) (very low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
All‐cause mortality · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes mortality compared with lactulose (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes hepatic encephalopathy assessed based on neurocognitive manifestations compared with lactulose (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Quality of life assessed using questionnaires · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG may leads to lower need for additional therapies compared with lactulose (low certainty).
1 finding from 1 review
Successful disimpaction · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG may leads to lower successful disimpaction compared with lactulose (low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in adverse events compared with lactulose (moderate certainty).
1 finding from 1 review